Inclusion Criteria:

          -  Histologically-proven recurrent squamous cell carcinoma of the head and neck (SCCHN),
             who has received prior radiotherapy with or without chemotherapy. New primary is
             allowed if location is in a previously irradiated field. Biopsy is recommended for
             each recurrence but is not mandated per study. This will be at the discretion of the
             principal investigator.

          -  Prior radiation dose of at least 50 Gy.

          -  Disease confined to locoregional site and can be encompassed in a stereotactic body
             radiosurgery "portal"

          -  Tumor must be deemed to be inoperable or unresectable either by clinical or
             radiographic criteria. These criteria include encasement of great vessels, vertebral
             invasion or undue peri-operative risk.

          -  Prior surgery for recurrent or new SCCHN is allowed in previously irradiated patients.
             A minimum of 4 weeks should elapse between any surgery and treatment on study.
             However, high-risk pathologic features should be present, such as positive margins,
             positive lymphadenopathy, perineural or angiolymphatic invasion.

          -  Karnofsky performance status > 60 (ECOG 0-1)

          -  Prior treatment with an EGFR Inhibitor is allowed if it was a part of prior curative
             therapy and was completed at least 30 days prior to commencement of study therapy

          -  Any number of prior chemotherapy regimens are allowed

          -  Measurable disease on imaging studies (MRI, CT, PET-CT or physical exam)

          -  Age > 18

          -  Estimated life expectancy > 12 weeks

          -  No prior radiation therapy or chemotherapy within 1 month of study enrollment

          -  ANC > 1000, PLT>75,000, Serum creatinine<2.5 mg/dL, Bilirubin <1.5 x upper limits of
             normal (ULN)

          -  Diabetes must be controlled prior to PET-CT scanning (blood glucose <200 mg/dL)

          -  Ability to provide written informed consent

        Exclusion Criteria:

          -  Evidence of distant metastasis on upright chest x-ray (CXR), computed tomography (CT)
             or other staging studies

          -  Patients in their reproductive age group should use an effective method of birth
             control. Patients who are breast-feeding, or have a positive pregnancy test will be
             excluded from the study

          -  Any co-morbidity or condition of sufficient severity to limit full compliance with the
             protocol per assessment by the investigator

          -  Concurrent serious infection

          -  History of known hypersensitivity to cetuximab, docetaxel or similar agents